e-therapeutics PLC – Annual Results

London, UK, 6 June 2024: e-therapeutics PLC, a company integrating computational power and biological data to discover life-transforming RNAi medicines, today announced its audited results for the year ended 31 January 2024 and provided an update on recent pipeline progress.

“The 2023/24 financial year was an important time for e-therapeutics, marking the beginning of a period of effective execution in advancing our therapeutic pipeline. During the year we delivered solid pipeline progress, generating positive preclinical proof-of-concept data for four GalOmic™ RNAi assets discovered in-house.” commented Ali Mortazavi, Chief Executive Officer

Post period operational highlights:

Successful fundraise of £28.9 million announced in April 2024 by way of a subscription by funds managed by M&G Investment Management Limited and Richard Griffiths, both existing shareholders of the Company.

Completed cancellation of admission of our Ordinary Shares to trading on AIM as of 9 May 2024.

Strengthened the Board of Directors with the appointment of Lord David Prior as Chair, as of 23 May 2024.

The Annual General Meeting will be held at 12:30 p.m. on Tuesday, 16 July 2024, at the Company’s registered office at 4 Kingdom Street, Paddington, London W2 6BD.

Please find the full results here.